The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.
|Number of pages||3|
|Journal||European Journal of Pharmacology|
|State||Published - Dec 28 2008|
Bibliographical noteFunding Information:
This work was supported by USPHS grant U19 DA17548. For purposes of full disclosure, the University of Kentucky holds patents on bPiDDB and a potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.
- Dopamine metabolism
- Nicotinic receptor
- Nucleus accumbens
ASJC Scopus subject areas